We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+25.82%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$11.2M
Cap. Flow
+$12.8M
Cap. Flow %
7.01%
Top 10 Hldgs %
33.05%
Holding
110
New
26
Increased
27
Reduced
30
Closed
19

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$9.45M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$6.59M
3
MRUS
Merus
MRUS
+$5.65M
4
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$5.12M
5
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$4.14M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$7.21M
2
EPIX
ESSA Pharma
EPIX
+$5.8M
3
DCTH icon
Delcath Systems
DCTH
+$5.74M
4
STRO icon
Sutro Biopharma
STRO
+$4.02M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 85.57%
2 Financials 3.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
26
Larimar Therapeutics
LRMR
$398M
$2.8M 1.53%
191,945
-25,258
-12% -$459K
BIIB icon
27
CALL
Biogen
BIIB
$30.7B
$2.8M 1.53%
10,000
-20,000
-67% -$5.39M
ADMS
28
DELISTED
Adamas Pharmaceuticals
ADMS
$2.51M 1.37%
522,589
+81,634
+19% +$426K
ASND icon
29
Ascendis Pharma A/S
ASND
$16.5B
$2.41M 1.31%
18,694
+1,138
+6% +$173K
MLTX icon
30
MoonLake Immunotherapeutics
MLTX
$1.62B
$2.33M 1.27%
228,485
+13,414
+6% +$148K
SRRA
31
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.32M 1.27%
134,681
-319
-0.2% -$5.05K
KURA icon
32
Kura Oncology
KURA
$826M
$2.26M 1.23%
80,000
-10,000
-11% -$316K
EPIX
33
DELISTED
ESSA Pharma
EPIX
$2.13M 1.16%
73,451
-249,466
-77% -$5.8M
MCRB icon
34
Seres Therapeutics
MCRB
$46.3M
$2.06M 1.12%
5,000
+3,750
+300% +$1.73M
SRRK icon
35
Scholar Rock
SRRK
$5.87B
$1.83M 1%
36,221
+11,221
+45% +$621K
ONCR
36
DELISTED
Oncorus, Inc.
ONCR
$1.81M 0.99%
+130,000
New +$2.69M
DCPH
37
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.78M 0.97%
39,765
+1,145
+3% +$53.3K
BGMS
38
Bio Green Med Solution Inc
BGMS
$5.04M
$1.78M 0.97%
+69
New +$1.94M
EVGN icon
39
Evogene
EVGN
$5.92M
$1.76M 0.96%
35,000
-25,000
-42% -$1.55M
ODT
40
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$1.71M 0.93%
+500,000
New +$9.45M
ARVN icon
41
Arvinas
ARVN
$536M
$1.66M 0.9%
25,071
-29,929
-54% -$2.29M
VRTX icon
42
Vertex Pharmaceuticals
VRTX
$122B
$1.61M 0.88%
7,500
+2,500
+50% +$549K
TPTX
43
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.58M 0.86%
16,741
+610
+4% +$72.5K
GH icon
44
Guardant Health
GH
$20.2B
$1.56M 0.85%
10,192
-8,633
-46% -$1.3M
SAGE
45
CALL
DELISTED
Sage Therapeutics
SAGE
$1.5M 0.82%
+20,000
New +$1.64M
CHRS icon
46
Coherus Oncology
CHRS
$227M
$1.46M 0.8%
+100,000
New +$1.7M
FULC icon
47
Fulcrum Therapeutics
FULC
$248M
$1.43M 0.78%
121,302
+105,093
+648% +$1.3M
BIIB icon
48
Biogen
BIIB
$30.7B
$1.4M 0.76%
5,000
+2,000
+67% +$539K
ARNA
49
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.39M 0.76%
20,000
– –
PYPD icon
50
PolyPid
PYPD
$83.8M
$1.37M 0.75%
+4,994
New +$1.63M
1
2
3 4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Silverarc Capital Management held 110 positions worth $183M, up 6.5% from $172M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Silverarc Capital Management deployed $12.8M of net new capital in Q1 2021, opening 26 new positions and adding to 27 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Vericel Corp, an estimated $7.21M trimmed.

  • Silverarc Capital Management's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
  • Silverarc Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021, an estimated $2.72M increase.
  • Silverarc Capital Management's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $7.21M.
  • Silverarc Capital Management fully exited Sutro Biopharma in Q1 2021, selling an estimated $4.02M.
  • Silverarc Capital Management's ten largest holdings make up 33% of its $183M portfolio in Q1 2021.
  • Silverarc Capital Management opened 26 new positions and closed 19 in Q1 2021.
  • Silverarc Capital Management's portfolio value rose 6.5% quarter-over-quarter to $183M.

Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.